Skip to content

Food Frequency Questionnaire (FFQ) for Coronary Heart Disease (CHD) Patients

Evaluation of the Psychometric Properties of a Food Frequency Questionnaire Developed for Patients With Coronary Heart Disease in Northern China

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03292055
Enrollment
235
Registered
2017-09-25
Start date
2017-01-13
Completion date
2017-12-15
Last updated
2018-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

food frequency questionnaire; psychometric properties

Brief summary

This study aims to evaluate the psychometric properties of a newly developed FFQ specified for northern Chinese CHD and their high risk patients (CHD-FFQ). The psychometric properties include test-retest reliability, content validity, convergent validity, discriminant validity, concurrent validity and predictive validity. Particularly, this study will measure the physiological indicators, including plasma lipid profile (i.e. TG, TC, HDL-C, LDL-C), BG, BP and BMI twice at baseline and the end. The level of these physiological indicators will be compared with the fat intake measured by the CHD-FFQ, i.e. the baseline intake to test its convergent validity. It is also expected to predict the diet-related progression of CHD risks among high-risk individuals, i.e. patients with two or more CHD risk factors as following: raised fasting blood glucose (BG) level, increased blood pressure (BP), increased triglycerides (TG), decreased HDL-Cholesterol (HDL-C), increased LDL-Cholesterol (LDL-C), smoking and central obesity (International Diabetes Federation, 2015). In addition, this study will provide the FFQ's concurrent validity in assessing the intake of energy and nutrients against the CDC-FFQ. Moreover, whether the FFQ could detect the known differences in energy intake between men and women will be established for its discriminant validity.

Interventions

None listed

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older; * Have no CHD at enrollment; * At high risk of CHD with at least two of the following risk factors: * current smoking: current smokers are defined as individuals who smoked regularly during the last 12 months * central obesity: for Chinese, central obesity is defined as waist circumstance above 90cm for male and 80cm for female, or with BMI above 30kg/m² * raised BP (systolic BP \[SBP\] ≥ 130 mmHg or diastolic BP \[DBP\] ≥85 mmHg or under antihypertensive treatment) * raised fasting BG (FBG) (100mg/dL \[5.6mmol/L\]) or under treatment with insulin or oral hypoglycemic agents * elevated TG (150mg/dL \[1.7mmol/L\]) * elevated TC (≥ 240 mg/dL \[5.18 mmol/L\]) * raised LDL-C (≥ 160 mg/dL \[4.15 mmol/L\]) * decreased HDL-C (\<40 mg/dL \[1.03 mmol/L\] for males, and \<50 mg/dL \[1.29 mmol/L\] for females) * undergoing hyperlipidemia treatment

Exclusion criteria

* Impaired bilateral hearing * Impaired mental status (according to their medical record)

Design outcomes

Primary

MeasureTime frameDescription
Blood pressureJanuary-February, April- May, July- August, October- NovemberTo take the blood pressure, the participant will be asked to be seated for at least 15 minutes with his/her legs uncrossed (WHO, 2008). Two BP measurements will be taken and between the two readings, the participant will have three minutes' rest.
HeightJanuary-February, April- May, July- August, October- NovemberParticipant's height will be measured to the nearest 0.5 cm, with a right-angle triangle resting on the scalp and against the wall, having the back square against the wall tape and eyes looking straight ahead. The height will be measured without wearing shoes.
WeightJanuary-February, April- May, July- August, October- NovemberA calibrated scale with the resolution of 0.1 kg will be used to measure the weight of the participants, who will be asked to wear light clothes during measurement. The weight will be measured without shoes.
BMIJanuary-February, April- May, July- August, October- Novemberweight and height will be combined to report BMI in kg/m\^2
Waist circumstanceJanuary-February, April- May, July- August, October- NovemberWaist circumstance will be taken at the midpoint between the top of the iliac crest and the lower margin of the palpable rib
Intake of FoodJanuary-February, April- May, July- August, October- NovemberThe newly developed FFQ (CHD-FFQ) will be applied to the participants to collect their dietary intake of food.
Cardiac-related physiological blood parametersJanuary- February, October- NovemberIn the beginning and the end of the study, the medical records of the participants will be refered to get the blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in the past three months, in the department and the community centers.

Secondary

MeasureTime frameDescription
Sociodemographic informationJanuary-FebruaryAge, gender, marital status, occupation, educational level, living conditions, financial background, and living areas will be collected using a self-developed questionnaire.
General clinical informationJanuary-FebruarySmoking history, family history and clinical data will be collected using a self-developed questionnaire.
Physical activity levelJanuary-February, April- May, July- August, October- NovemberThe physical activity level of the participants will be measured using the Chinese version of the short version of International Physical Activity Questionnaire (short- Chinese IPAQ).
Clinical InformationOctober- NovemberTheir clinical information on hospital readmission, surgery or medical procedures, and medication adjustment during the last year will be collected.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026